

(19)



(11)

**EP 3 514 237 A1**

(12)

**EUROPEAN PATENT APPLICATION**  
published in accordance with Art. 153(4) EPC

(43) Date of publication:

**24.07.2019 Bulletin 2019/30**

(51) Int Cl.:

**C12N 15/115** <sup>(2010.01)</sup>      **C12N 15/09** <sup>(2006.01)</sup>  
**C12Q 1/68** <sup>(2018.01)</sup>      **G01N 33/53** <sup>(2006.01)</sup>

(21) Application number: **17850476.7**

(86) International application number:

**PCT/JP2017/015934**

(22) Date of filing: **20.04.2017**

(87) International publication number:

**WO 2018/051569 (22.03.2018 Gazette 2018/12)**

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB  
 GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO  
 PL PT RO RS SE SI SK SM TR**

Designated Extension States:

**BA ME**

Designated Validation States:

**MA MD**

- **HORII, Katsunori**  
Tokyo 136-8627 (JP)
- **AKITOMI, Jou**  
Tokyo 136-8627 (JP)
- **KANEKO, Naoto**  
Tokyo 136-8627 (JP)
- **WAGA, Iwao**  
Tokyo 136-8627 (JP)
- **KUWAHARA, Masayasu**  
Maebashi-shi  
Gunma 371-8510 (JP)

(30) Priority: **15.09.2016 JP 2016180892**

(71) Applicants:

- **NEC Solution Innovators, Ltd.**  
Koto-ku, Tokyo 136-8627 (JP)
- **National University Corporation Gunma University**  
Maebashi-shi, Gunma 371-8510 (JP)

(74) Representative: **Glawe, Delfs, Moll**  
Partnerschaft mbB von  
Patent- und Rechtsanwälten  
Postfach 13 03 91  
20103 Hamburg (DE)

(72) Inventors:

- **MINAGAWA, Hirotaka**  
Tokyo 136-8627 (JP)

(54) **SECRETORY IMMUNOGLOBULIN A (SIGA)-BINDING NUCLEIC ACID MOLECULE, SENSOR FOR SIGA ANALYSIS, AND ANALYSIS METHOD FOR SIGA**

(57) The present invention provides a novel molecule that can be used for detection of slgA. The slgA-binding nucleic acid molecule of the present invention is characterized in that it binds to secretory immunoglobulin A (slgA) with a dissociation constant of 37.7 nM or less, and preferably includes a polynucleotide consisting of any of base sequences of SEQ ID NOs: 1 to 12 or a partial sequence thereof, for example. According to the slgA-binding nucleic acid molecule of the present invention, it is possible to detect slgA in saliva.




FIG. 1A

**EP 3 514 237 A1**

**Description**

TECHNICAL FIELD

5 **[0001]** The present invention relates to a sIgA-binding nucleic acid molecule, a sIgA analysis sensor, and a sIgA analysis method.

BACKGROUND ART

10 **[0002]** From the fact that stress can cause fatigue and depression, great importance is placed on stress check in recent years. However, there is a problem in that it is difficult to check whether a person is under stress by other persons owing to the fact that the person himself/herself may not be aware of the stress or that the stress is a subjective matter, for example. Under these circumstances, there is a demand for the establishment of a method for checking stress objectively.

15 **[0003]** It is known that, when humans feel stress, secretion of sIgA in saliva increases. On this account, there has been an attempt to evaluate stress indirectly by measuring sIgA in the saliva. Specifically, an ELISA method using an antibody against sIgA as an antigen has been reported (Non Patent Literature 1).

**[0004]** However, antibodies are proteins and thus have a problem in stability. Accordingly, it is difficult to use an antibody in a test method that can be carried out easily at low cost.

20

Citation List

Non Patent Literature

25 **[0005]** Non Patent Literature 1: Isowa Keiko, "Relationship between Stressor in Duties of Nurses, Burnouts, and Physical Health Issues: Examination from Questionnaires and Immune Indicators", Behavioral Medicine Research, Vol. 10, No. 1, pp. 25-33

SUMMARY OF INVENTION

30

Technical Problem

**[0006]** With the foregoing in mind, the present invention is intended to provide a novel molecule that can be used for detection of sIgA.

35

Solution to Problem

**[0007]** The present invention provides a secretory immunoglobulin A (sIgA)-binding nucleic acid molecule that binds to sIgA with a dissociation constant of 37.7 nM or less.

40 **[0008]** The present invention also provides a sIgA analysis sensor including the sIgA-binding nucleic acid molecule of the present invention.

**[0009]** The present invention also provides a sIgA analysis method including the step of causing a specimen and a nucleic acid molecule to come into contact with each other to detect a sIgA in the specimen, wherein the nucleic acid molecule is the sIgA-binding nucleic acid molecule of the present invention, and

45 in the detection step, the nucleic acid molecule is caused to bind to the sIgA in the specimen, and the sIgA in the specimen is detected by detecting the binding.

Advantageous Effects of Invention

50 **[0010]** The sIgA-binding nucleic acid molecule of the present invention can bind to sIgA with the above-described dissociation constant. Thus, the sIgA-binding nucleic acid molecule of the present invention can detect sIgA in a specimen with high accuracy on the basis of the presence or absence of the binding with the sIgA, for example. Therefore, it can be said that the sIgA-binding nucleic acid molecule of the present invention is a very useful tool for the detection of sIgA in the fields of preventive medicine, health care, diagnoses of infectious diseases, diagnoses of stress, and the like, for example.

55

## BRIEF DESCRIPTION OF DRAWINGS

**[0011]**

5 FIG. 1A is a graph showing the binding ability of aptamers to slgA in Example 3.  
 FIG. 1B is a graph showing the binding ability of other aptamers to slgA in Example 3.  
 FIG. 1C is a graph showing the binding ability of other aptamers to slgA in Example 3.  
 FIG. 1D is a graph showing the binding ability of other aptamers to slgA in Example 3.  
 FIG. 1E is a graph showing the binding ability of another aptamer to slgA in Example 3.  
 10 FIG. 1F is a graph showing the binding ability of other aptamers to slgA in Example 3.  
 FIG. 2A is a graph showing the relative values (relative units) of the binding amounts of aptamers of Example 3 to slgA.  
 FIG. 2B is a graph showing the relative values (relative units) of the binding amounts of other aptamers of Example 3 to slgA.  
 FIG. 2C is a graph showing the relative value (relative unit) of the binding amount of another aptamer of Example 3 to slgA.  
 15 FIG. 2D is a graph showing the relative values (relative units) of the binding amounts of other aptamers of Example 3 to slgA.  
 FIG. 3 is a graph showing the relative values of the binding amounts of the aptamers of Example 3.  
 FIGs. 4A and 4B are photographs showing the results of SDS-PAGE in Example 4.

20

## DESCRIPTION OF EMBODIMENTS

**[0012]** The slgA-binding nucleic acid molecule of the present invention includes, for example, the following polynucleotide (a) or a polynucleotide consisting of a partial sequence thereof:

25

(a) a polynucleotide consisting of any of base sequences of SEQ ID NOs: 1 to 12.

**[0013]** In the slgA-binding nucleic acid molecule of the present invention, the polynucleotide consisting of the partial sequence is, for example, at least one polynucleotide selected from the group consisting of the following polynucleotides (a1), (a2), (a3), and (a4):

30

- (a1) a polynucleotide consisting of any of base sequences of SEQ ID NOs: 13, 14, and 15;
- (a2) a polynucleotide consisting of either of base sequences of SEQ ID NOs: 16 and 17;
- (a3) a polynucleotide consisting of either of base sequences of SEQ ID NOs: 18 and 19; and
- 35 (a4) a polynucleotide consisting of either of base sequences of SEQ ID NOs: 20 and 21.

**[0014]** The slgA-binding nucleic acid molecule of the present invention may include, for example, a modified base, which is a base modified with a modifying group.

**[0015]** In the slgA-binding nucleic acid molecule of the present invention, the modified base is, for example, a modified purine base, which is a purine base modified with a modifying group. The modifying group is preferably an adenine residue.

40

**[0016]** In the slgA-binding nucleic acid molecule of the present invention, the modified base is a modified thymine, which is a thymine base modified with a modifying group, for example. The modifying group is preferably an adenine residue or a guanine residue.

**[0017]** In the slgA-binding nucleic acid molecule of the present invention, the polynucleotide may be a DNA, for example.

45

**[0018]** In the slgA analysis method of the present invention, the specimen may be at least one selected from the group consisting of saliva, urine, plasma, and serum, for example.

**[0019]** The present invention is described specifically below.

(1) slgA-binding nucleic acid molecule

50

**[0020]** As described above, the slgA-binding nucleic acid molecule (hereinafter also merely referred to as "nucleic acid molecule") of the present invention is characterized in that it binds to slgA with a dissociation constant of 37.7 nM or less.

**[0021]** The nucleic acid molecule of the present invention can bind to slgA, as mentioned above. The nucleic acid molecule of the present invention may bind to, for example, a heavy chain of immunoglobulin that constitutes slgA, a light chain of the immunoglobulin, both of them, the bridges (J-strands) of two IgAs, or a secretory component that is bound to a slgA. The slgA is not particularly limited, and the slgA may be derived from a human or a non-human animal, for example. Examples of the non-human animal include mice, rats, monkeys, rabbits, dogs, cats, horses, cows, and

55

pigs. Amino acid sequence information on human Ig alpha-1 chain C region is registered under Accession No. P01876 in UniProt (<http://www.uniprot.org/>), for example. Amino acid sequence information on human Ig alpha-2 chain C region is registered under Accession No. P01877 in UniProt (<http://www.uniprot.org/>), for example.

5 **[0022]** In the present invention, the expression "binds to sIgA" (and grammatical variations thereof) also is referred to as "has binding ability to sIgA" or "has binding activity to sIgA", for example. The binding between the nucleic acid molecule of the present invention and the sIgA can be determined by surface plasmon resonance (SPR) analysis or the like, for example. The analysis can be performed using ProteON (trade name, BioRad), for example. Since the nucleic acid molecule of the present invention binds to sIgA, it can be used for detection of the sIgA, for example.

10 **[0023]** The nucleic acid molecule of the present invention binds to sIgA with a dissociation constant of 37.7 nM or less, 10 nM or less, 8 nM or less, or 5 nM or less, for example. The minimum detectable concentration of the sIgA by the nucleic acid molecule of the present invention is 50 nM, 20 nM, or 10 nM, for example.

**[0024]** The nucleic acid molecule of the present invention may be, for example, a nucleic acid molecule including the following polynucleotide (a), examples of which are shown in Table 1 below. (a) a polynucleotide consisting of any of base sequences of SEQ ID NOs: 1 to 12.

15

20

25

30

35

40

45

50

55

[Table 1]

SEQ ID NO:	Modified base	Base sequence
1	MK4	5'-GGTTGGACGCAATCTCCCTAATCTACTACGATATCCAGATGGGAAGTACCCTGAAACTACAATGGCGGGCTTATC-3'
2	MK4	5'-GGTTGGACGCAATCTCCCTAATCAGATGATATCGAGATCGGAAGCCGACCGCATGAAACTACAATGGCGGGCTTATC-3'
3	MK4	5'-GGTTGGACGCAATCTCCCTAATCAAGCCACGGAGAGTCCGAGGTGACCATTAAAGCAGGAAACTACAATGGCGGGCTTATC-3'
4	MK4	5'-GGTTGGACGCAATCTCCCTAATCGATCTAGATGGTCTCGGGTATGGCTAGATAGAAACTACAATGGCGGGCTTATC-3'
5	NG7	5'-GGTTGGACGCAATCTCCCTAATCTGCTGATGTTTGTATTTCAAATTAGCCGCAGAAACTACAATGGCGGGCTTATC-3'
6	NG7	5'-GGTTGGACGCAATCTCCCTAATCTAAATAGATTTACACAGTGGATCCTTCAGAGGAAACTACAATGGCGGGCTTATC-3'
7	NG7	5'-GGTTGGACGCAATCTCCCTAATCAGACAATAATTAGAGTGTACCACCTGTGATGAAACTACAATGGCGGGCTTATC-3'
8	KS9	5'-GGTTGGACGCAATCTCCCTAATCGTATATCAAGCAGATGTGTTCACTGGGGAGAAACTACAATGGCGGGCTTATC-3'
9	KS9	5'-GGTTGGACGCAATCTCCCTAATCAAAGATATGCTAAGATAGATAGTTGGCTTGAAC TACAA TGGCGGGCTTATC-3'
10	KS9	5'-GGTTGGACGCAATCTCCCTAATCACCTGTACTGGTTATATGCCTGCCAACATGAAACTACAATGGCGGGCTTATC-3'
11	KS9	5'-GGTTGGACGCAATCTCCCTAATCTTTATACGTATGGACTTAGGCTTTGTTATAGAAACTACAATGGCGGGCTTATC-3'
12	KS9	5'-GGTTGGACGCAATCTCCCTAATCCTACTCTGTTTTATCAATTTAGCAAGTTATGAAACTACAATGGCGGGCTTATC-3'

**[0025]** The nucleic acid molecule of the present invention may be, for example, a nucleic acid molecule including a polynucleotide consisting of a partial sequence of any of the polynucleotides (a).

**[0026]** The polynucleotide consisting of the partial sequence may be, for example, at least one polynucleotide selected from the group consisting of the following polynucleotides (a1), (a2), (a3), and (a4).

- (a1) a polynucleotide consisting of any of base sequences of SEQ ID NOs: 13, 14, and 15;
- (a2) a polynucleotide consisting of either of base sequences of SEQ ID NOs: 16 and 17;
- (a3) a polynucleotide consisting of either of base sequences of SEQ ID NOs: 18 and 19; and
- (a4) a polynucleotide consisting of either of base sequences of SEQ ID NOs: 20 and 21.

**[0027]** The polynucleotide (a1) defines examples of a partial sequence of SEQ ID NO: 5. The polynucleotide (a2) defines examples of a partial sequence of SEQ ID NO: 8. The polynucleotide (a3) defines examples of a partial sequence of SEQ ID NO: 11. The polynucleotide (a4) defines examples of a partial sequence of SEQ ID NO: 12. These sequences are shown in Table 2 below.

[Table 2]

SEQ ID NO:	Modified base	Base sequence
13	NG7	5'-GGTTTGGACGCAATCTCCCTAATCTGCTGATGTTTGTATTTCAAATTAGCCGCAG-3'
14	NG7	5'-GCAATCTCCCTAATCTGCTGATGTTTGTATTTCAAATTAGCCGCAG-3'
15	NG7	5'-GCAATCTCCCTAATCTGCTGATGTTTGTATTTCAAATTAGC-3'
16	KS9	5'-GGTTTGGACGCAATCTCCCTAATCGTATATCAAGCAGATGTGTTCACTTGGGGAG-3'
17	KS9	5'-GCAATCTCCCTAATCGTATATCAAGCAGATGTGTTCACTTGGGGAG-3'
18	KS9	5'-GGTTTGGACGCAATCTCCCTAATCAAAGATATGCTAAGATAGATAGTTTGGCTTG-3'
19	KS9	5'-GCAATCTCCCTAATCAAAGATATGCTAAGATAGATAGTTTGGCTTG-3'
20	KS9	5'-GGTTTGGACGCAATCTCCCTAATCTTTATACGTATGGACTTAGGCTTTGTTATAGAAAC-3'
21	KS9	5'-GCAATCTCCCTAATCTTTATACGTATGGACTTAGGCTTTGTTATAGAAAC-3'

**[0028]** In the binding nucleic acid molecule of the present invention, the polynucleotide encompasses, for example, at least one polynucleotide selected from the group consisting of the following polynucleotides (b) to (d):

- (b) a polynucleotide that consists of a base sequence obtained by deletion, substitution, insertion, and/or addition of one or more bases in any of the base sequences of the polynucleotide (a) and binds to the slgA;
- (c) a polynucleotide that consists of a base sequence having at least 80% sequence identity to any of the base sequences of the polynucleotide (a) and binds to the slgA; and
- (d) a polynucleotide that consists of a base sequence complementary to a polynucleotide hybridizing to any of the base sequences of the polynucleotide (a) under stringent conditions and binds to the slgA.

**[0029]** Regarding the polynucleotide (b), the term "one or more" is not limited as long as, for example, it is in the range where the polynucleotide (b) binds to slgA. The number of the "one or more" bases is, for example, 1 to 10, 1 to 7, 1 to 5, 1 to 3, or 1 or 2. In the present invention, the numerical range regarding the number of bases, sequences, or the like discloses, for example, all the positive integers falling within that range. That is, for example, the description "1 to 5 bases" discloses all of "1, 2, 3, 4, and 5 bases" (the same applies hereinafter).

**[0030]** Regarding the polynucleotide (c), the "sequence identity" is not limited as long as, for example, it is in the range where the polynucleotide (c) binds to slgA. The sequence identity is, for example, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%. The sequence identity can be calculated with analysis software such as BLAST or FASTA using default parameters, for example (the same applies hereinafter).

**[0031]** Regarding the polynucleotide (d), the "polynucleotide hybridizing to" may be, for example, a polynucleotide that is perfectly or partially complementary to the polynucleotide (a) and binds to the slgA. The hybridization can be detected by various types of hybridization assay, for example. The hybridization assay is not particularly limited, and for example, a method described in "Molecular Cloning: A Laboratory Manual 2nd Ed." edited by Sambrook et al. (Cold Spring Harbor

Laboratory Press (1989)) or the like can be employed.

[0032] Regarding the polynucleotide (d), the "stringent conditions" may be any of low stringency conditions, medium stringency conditions, and high stringency conditions, for example. The "low stringency conditions" are, for example, conditions where  $5 \times \text{SSC}$ ,  $5 \times \text{Denhardt's solution}$ , 0.5% SDS, and 50% formamide are used at 32°C. The "medium stringency conditions" are, for example, conditions where  $5 \times \text{SSC}$ ,  $5 \times \text{Denhardt's solution}$ , 0.5% SDS, and 50% formamide are used at 42°C. The "high stringency conditions" are, for example, conditions where  $5 \times \text{SSC}$ ,  $5 \times \text{Denhardt's solution}$ , 0.5% SDS, and 50% formamide, are used at 50°C. Those skilled in the art can set the degree of stringency by, for example, setting the conditions such as the temperature, the salt concentration, the concentration and length of a probe, the ionic strength, the time, etc. as appropriate. As the "stringent conditions", it is also possible to employ conditions described in the above-described "Molecular Cloning: A Laboratory Manual 2nd Ed." edited by Sambrook et al. (Cold Spring Harbor Laboratory Press (1989)) or the like, for example.

[0033] The polynucleotides (a1) to (a4) are each a partial sequence of the polynucleotide (a). Thus, it can be said that they each define examples of the polynucleotide (b), (c), or (d), for example. When the nucleic acid molecule of the present invention is consisting of polynucleotides of (a1) to (a4), base sequences of the polynucleotide (a) in the polynucleotides (b) to (d) are the respective base sequences of the polynucleotides (a1) to (a4). In the description of the polynucleotides (b) to (d), "any of the base sequences of the polynucleotide (a)" and "polynucleotide (a)" can be read as "any of the base sequences of the polynucleotide (a1)" and "any of the polynucleotides (a1)", "any of the base sequences of the polynucleotide (a2)" and "any of the polynucleotides (a2)", "any of the base sequences of the polynucleotide (a3)" and "any of the polynucleotides (a3)", or "any of the base sequences of the polynucleotide (a4)" and "any of the polynucleotides (a4)", and the description of these can be incorporated in the description of "any of the base sequences of the polynucleotide (a)" and "polynucleotide (a)" by reference.

[0034] In the nucleic acid molecule of the present invention, the building blocks of the polynucleotide are, for example, nucleotide residues, examples of which include deoxyribonucleotide residues and ribonucleotide residues. The polynucleotide is, for example, a DNA consisting of deoxyribonucleotide residues or a DNA including a deoxyribonucleotide residue(s) and a ribonucleotide residue(s), and the polynucleotide may further include a non-nucleotide residue(s), as mentioned below. Hereinafter, the slgA-binding nucleic acid molecule of the present invention is also referred to as an aptamer, for example.

[0035] The nucleic acid molecule of the present invention may consist of any of the above-described polynucleotides, or may include any of the above-described polynucleotides, for example. In the latter case, the nucleic acid molecule of the present invention may include, for example, two or more polynucleotides selected from the above-described polynucleotides, as mentioned below. The two or more polynucleotides may be the polynucleotides with the same sequence or different sequences. Also, in the latter case, the nucleic acid molecule of the present invention further may include a linker(s) and/or an additional sequence(s), for example. The linker is a sequence present between polynucleotides, for example. The additional sequence is a sequence added to an end, for example.

[0036] When the nucleic acid molecule of the present invention includes, for example, a plurality of polynucleotides selected from the above-described polynucleotides, it is preferable that the plurality of polynucleotide sequences are linked to each other to form a single-stranded polynucleotide. The plurality of polynucleotide sequences may be linked to each other directly, or may be linked to each other indirectly with a linker, for example. It is preferable that the polynucleotide sequences are linked to each other directly or indirectly at their ends. When the nucleic acid molecule of the present invention includes the plurality of polynucleotide sequences, the number of the sequences is not particularly limited, and is, for example, 2 or more, 2 to 20, 2 to 10, or 2 or 3.

[0037] The length of the linker is not particularly limited, and is, for example, 1- to 200-mer, 1- to 20-mer, 3- to 12-mer, or 5- to 9-mer. The building blocks of the linker are, for example, nucleotide residues, examples of which include deoxyribonucleotide residues and ribonucleotide residues. The linker is not particularly limited, and examples thereof include polynucleotides such as a DNA consisting of deoxyribonucleotide residues and a DNA including a ribonucleotide residue(s). Specific examples of the linker include polydeoxythymine (poly[dT]), polydeoxyadenine (poly[dA]), and poly(dA-dT) having a repetitive sequence composed of A and T. Preferably, the linker is poly(dT) or poly(dA-dT).

[0038] In the nucleic acid molecule of the present invention, the polynucleotide preferably is a single-stranded polynucleotide. It is preferable that the single-stranded polynucleotide can form a stem structure and a loop structure by self-annealing, for example. It is preferable that the polynucleotide can form a stem-loop structure, an internal loop structure, and/or a bulge structure, for example.

[0039] The nucleic acid molecule of the present invention may be a double strand, for example. When the nucleic acid molecule is a double strand, for example, one of single-stranded polynucleotides includes the polynucleotide (a), a partial sequence thereof, or any of the polynucleotides (b) to (d), and the other single-stranded polynucleotide is not limited. The other single-stranded polynucleotide may be, for example, a polynucleotide including a base sequence complementary to any of the polynucleotides (a) to (d). When the nucleic acid molecule of the present invention is a double strand, it is preferable to dissociate the double strand to single-stranded polynucleotides by denaturation or the like before use, for example. Also, it is preferable that the dissociated single-stranded polynucleotide including any of the

polynucleotides (a) to (d) is forming a stem structure and a loop structure as mentioned above, for example.

**[0040]** In the present invention, the expression "can form a stem structure and a loop structure" encompasses that, for example, a stem structure and a loop structure are formed actually, and also, even if a stem structure and a loop structure are not formed, they can be formed depending on conditions. The expression "can form a stem structure and a loop structure (and grammatical variations thereof)" encompasses, for example, both the cases where the formation thereof has been confirmed through an experiment and where the formation thereof is predicted through simulation using a computer or the like.

**[0041]** The building blocks of the nucleic acid molecule of the present invention are, for example, nucleotide residues. Examples of the nucleotide residues include deoxyribonucleotide residues and ribonucleotide residues. The nucleic acid molecule of the present invention may be, for example, a DNA consisting of deoxyribonucleotide residues only or a DNA including one or more ribonucleotide residues. In the latter case, "one or more" is not particularly limited. For example, the number of the ribonucleotide residues in the polynucleotide is, for example, 1 to 91, 1 to 30, 1 to 15, 1 to 7, 1 to 3, or 1 or 2.

**[0042]** The polynucleotide may include, as a base in a nucleotide residue, a natural base or a modified base. The natural base (non-artificial base) is not particularly limited, and may be, for example, a purine base with a purine skeleton or a pyrimidine base with a pyrimidine skeleton. The purine base is not particularly limited, and examples thereof include adenine (a) and guanine (g). The pyrimidine base is not particularly limited, and examples thereof include cytosine (c), thymine (t), and uracil (u). Among them, cytosine (c) and thymine (t) are preferable.

**[0043]** When the polynucleotide includes the modified base(s), the site and the number of the modified bases are not particularly limited. When the partial sequence of the polynucleotide (a) has the modified base(s), some or all of the underlined adenines and thymines in the polynucleotides of Tables 1 and 2 are modified bases, for example. When the underlined adenine is the modified base, the modified base is a modified purine base, which is a purine base modified with a modifying group. When the underlined thymine is the modified base, the modified base is a modified thymine, which is a thymine base modified with a modifying group.

**[0044]** The modified base is a base modified with a modifying group, for example. The base to be modified with the modifying group (also referred to simply as the "base to be modified" hereinafter) is the natural base, for example. The natural base is not particularly limited, and may be, for example, a purine base or a pyrimidine base. The modified base is not particularly limited, and may be, for example, a modified adenine, a modified guanine, a modified cytosine, a modified thymine, or a modified uracil.

**[0045]** In the modified base, the base to be modified may be modified with the modifying group either directly or indirectly, for example. In the latter case, the base to be modified may be modified with the modifying group via a linker, for example. The linker is not particularly limited.

**[0046]** In the base to be modified, a site to be modified with the modifying group is not particularly limited. When the base is a purine base, the modified site in the purine base may be, for example, the 7-position or the 8-position, preferably the 7-position of the purine skeleton. When the modified site in the purine base is the 7-position of the purine skeleton, the nitrogen atom at the 7-position is preferably substituted with a carbon atom. When the base is a pyrimidine base, the modified site in the pyrimidine base may be, for example, the 5-position or the 6-position, preferably the 5-position of the pyrimidine skeleton. Thymine has a methyl group bound to carbon at the 5-position. Thus, when the 5-position of the pyrimidine base is modified, for example, the modifying group may be bound to the carbon at the 5-position either directly or indirectly, or the modifying group may be bound to carbon in the methyl group bound to the carbon at the 5-position either directly or indirectly. When the pyrimidine skeleton has "=O" bound to carbon at the 4-position and a group that is not "-CH<sub>3</sub>" or "-H" bound to carbon at the 5-position, the modified base can be referred to as a modified uracil or a modified thymine.

**[0047]** When the modified base is a modified purine base, the modifying group is preferably an adenine residue. That is, the modified purine base is a base modified with an adenine residue, for example. In the base to be modified, a site to be modified with the adenine residue (binding site of the adenine residue to the base to be modified) is not particularly limited, and can be, for example, an amino group that binds to carbon at the 6-position of the adenine residue. The base to be modified with the adenine residue is not particularly limited, and preferably is a purine base, for example, and it is preferable that atom at the 7-position of the purine base is modified with the adenine residue. When the modified base is a modified thymine base, the modifying group is preferably an adenine residue or a guanine base. That is, the modified base is, for example, a base modified with an adenine residue or a guanine residue. In the base to be modified, a site to be modified with the adenine residue is not particularly limited, and can be, for example, an amino group that binds to carbon at the 6-position of the adenine residue. In the base to be modified, a site to be modified with the guanine residue is not particularly limited, and can be, for example, an amino group that binds to carbon at the 2-position of the guanine residue. The base to be modified with the adenine residue or the guanine residue is not particularly limited, and preferably is a thymine, for example, and it is preferable that carbon in a methyl group bound to the carbon at the 5-position of the thymine is modified with the adenine residue or the guanine residue.

**[0048]** When the modifying group is the adenine residue or the guanine residue, it is preferable that, for example, the base to be modified is modified with the modifying group via the linker, as shown below.

[nucleotide residue]-[linker]-[adenine residue]  
 [nucleotide residue]-[linker]-[guanine residue]

5 **[0049]** The linker is not particularly limited, and can be represented by, for example, each formula present between the nucleotide residue and the adenine residue/guanine residue, as shown below. It is to be noted, however, that the linker is not limited thereto. In each formula, the numerical value "n" in (CH<sub>2</sub>)<sub>n</sub> is 1 to 10, 2 to 10, or 2, for example.

10 [nucleotide residue]=C-C(=O)-NH-(CH<sub>2</sub>)<sub>n</sub>-[adenine residue]  
 [nucleotide residue]=C-C(=O)-NH-(CH<sub>2</sub>)<sub>n</sub>-[guanine residue]  
 [nucleotide residue]-C=C-C(=O)-NH-(CH<sub>2</sub>)<sub>n</sub>-[adenine residue]  
 [nucleotide residue]=C-C(=O)-NH-CH<sub>2</sub>-CH<sub>2</sub>-[adenine residue]  
 [nucleotide residue]=C-C(=O)-NH-CH<sub>2</sub>-CH<sub>2</sub>-[guanine residue]  
 [nucleotide residue]-C=C-C(=O)-NH-CH<sub>2</sub>-CH<sub>2</sub>-[adenine residue]

15 **[0050]** In each formula, one ends of the linker [=C] and [-C] form a double bond and a single bond with carbon of the base to be modified in the nucleotide residue, respectively, for example, and the other end of the linker [CH<sub>2</sub>] is bound to amine (-NH) in the adenine residue or the guanine residue, for example.

20 **[0051]** Specific examples of an adenosine (purine derivative where the nitrogen atom at the 7-position is substituted with a carbon atom) nucleotide residue modified with the adenine residue in the polynucleotide include a residue represented by the following chemical formula (1) (also referred to as "MK4" hereinafter). Specific examples of a thymidine nucleotide residue modified with the adenine residue in the polynucleotide include a residue represented by the following chemical formula (2) (also referred to as "KS9" hereinafter). Specific examples of a thymidine nucleotide residue modified with the guanine residue in the polynucleotide include a residue represented by the following formula (3) (also referred to as "NG7" hereinafter). It is to be noted, however, that the present invention is not limited thereto.

25

30

35

40

45

50

55

5

10

15

20

25

30


35

40


45

50

55



... (1)



... (2)




5

10

15

20




25

30

35


40



45

50

55



[0054] Other examples of the modifying group include methyl group, fluoro group, amino groups, thio group, a ben-

zylaminocarbonyl group, a tryptaminocarbonyl group, and an isobutylaminocarbonyl group.

**[0055]** Specific examples of the modified adenine include 7'-deazaadenine. Specific examples of the modified guanine include 7'-deazaguanine. Specific examples of the modified cytosine include 5'-methylcytosine (5-Me-dC). Specific examples of the modified thymine include 5'-benzylaminocarbonyl thymine, 5'-tryptaminocarbonyl thymine, and 5'-isobutylaminocarbonyl thymine. Specific examples of the modified uracil include 5'-benzylaminocarbonyl uracil (BndU), 5'-tryptaminocarbonyl uracil (TrpdU), and 5'-isobutylaminocarbonyl uracil. The modified uracils given above as examples also can be referred to as modified thymines.

**[0056]** The polynucleotide may include only one type or two or more types of the modified bases, for example.

**[0057]** The nucleic acid molecule of the present invention may be a modified nucleotide, for example. The modified nucleotide may be a nucleotide having the above-described modified base, a nucleotide having a modified sugar obtained through modification of a sugar residue, or a nucleotide having the modified base and the modified sugar.

**[0058]** The sugar residue is not particularly limited, and may be a deoxyribose residue or a ribose residue, for example. The modified site in the sugar residue is not particularly limited, and may be, for example, the 2'-position or the 4'-position of the sugar residue. Either one or both of the 2'-position and the 4'-position may be modified. Examples of a modifying group in the modified sugar include methyl groups, fluoro groups, amino groups, and thio groups.

**[0059]** When the base in the modified nucleotide residue is a pyrimidine base, it is preferable that the 2'-position and/or the 4'-position of the sugar residue is modified, for example. Specific examples of the modified nucleotide residue include modified nucleotide residues with the 2'-position of the deoxyribose residue or ribose residue being modified, such as a 2'-methylated-uracil nucleotide residue, 2'-methylated-cytosine nucleotide residue, 2'-fluorinated-uracil nucleotide residue, 2'-fluorinated-cytosine nucleotide residue, 2'-aminated-uracil nucleotide residue, 2'-aminated-cytosine nucleotide residue, 2'-thiated-uracil nucleotide residue, and 2'-thiated-cytosine nucleotide residue.

**[0060]** The number of the modified nucleotides is not particularly limited. For example, the number of the modified nucleotides in the polynucleotide is, for example, 1 to 100, 1 to 90, 1 to 80, or 1 to 70. Also, the number of the modified nucleotides in the full-length nucleic acid molecule including the polynucleotide is not particularly limited, and is, for example, 1 to 91, 1 to 78, or in the numerical ranges given above as examples of the number of the modified nucleotides in the polynucleotide.

**[0061]** The nucleic acid molecule of the present invention may include, for example, one or more artificial nucleic acid monomer residues. The term "one or more" is not particularly limited, and may be, for example, 1 to 100, 1 to 50, 1 to 30, or 1 to 10 in the polynucleotide, for example. Examples of the artificial nucleic acid monomer residue include peptide nucleic acids (PNAs), locked nucleic acids (LNAs), and 2'-O,4'-C-ethylenebridged nucleic acids (ENAs). The nucleic acid in the monomer residue is the same as described above, for example.

**[0062]** It is preferable that the nucleic acid molecule of the present invention is resistant to nuclease, for example. In order to allow the nucleic acid molecule of the present invention to have nuclease resistance, it is preferable that the nucleic acid molecule of the present invention includes the modified nucleotide residue(s) and/or the artificial nucleic acid monomer residue(s), for example. Also, in order to allow the nucleic acid molecule of the present invention to have nuclease resistance, the nucleic acid molecule of the present invention may have polyethylene glycol (PEG) of several tens of kDa, deoxythymidine, or the like bound to, e.g., the 5' end or the 3' end thereof.

**[0063]** The nucleic acid molecule of the present invention may further include an additional sequence, for example. Preferably, the additional sequence is bound to at least one of the 5' end and the 3' end, more preferably to the 3' end of the nucleic acid molecule, for example. The additional sequence is not particularly limited. The length of the additional sequence is not particularly limited, and is, for example, 1- to 200-mer, 1- to 50-mer, 1- to 25-mer, or 18- to 24-mer. The building blocks of the additional sequence are, for example, nucleotide residues, examples of which include deoxyribonucleotide residues and ribonucleotide residues. The additional sequence is not particularly limited, and examples thereof include polynucleotides such as a DNA consisting of deoxyribonucleotide residues and a DNA including a ribonucleotide residue(s). Specific examples of the additional sequence include poly(dT) and poly(dA).

**[0064]** The nucleic acid molecule of the present invention can be used in the state where it is immobilized on a carrier, for example. It is preferable to immobilize either the 5' end or the 3' end, more preferably the 3' end of the nucleic acid molecule of the present invention, for example. When the nucleic acid molecule of the present invention is immobilized, the nucleic acid molecule may be immobilized either directly or indirectly on the carrier, for example. In the latter case, it is preferable to immobilize the nucleic acid molecule via the additional sequence, for example.

**[0065]** The method for producing the nucleic acid molecule of the present invention is not particularly limited. For example, the nucleic acid molecule of the present invention can be synthesized by known methods such as: nucleic acid synthesis methods utilizing chemical synthesis; and genetic engineering procedures. The nucleic acid molecule of the present invention also can be obtained by a so-called SELEX method, for example. In this case, a target preferably is sIgA.

**[0066]** The nucleic acid molecule of the present invention exhibits binding properties to the sIgA, as mentioned above. Thus, use of the nucleic acid molecule of the present invention is not particularly limited, as long as it is the use utilizing the binding properties of the nucleic acid molecule to the sIgA. The nucleic acid molecule of the present invention can

be used in various methods as an alternative to, e.g., an antibody against the slgA.

(2) slgA analysis sensor

5 **[0067]** As described above, the analysis sensor of the present invention is a slgA analysis sensor characterized in that it includes the nucleic acid molecule of the present invention. It is only required that the analysis sensor of the present invention includes the nucleic acid molecule of the present invention, and other configurations are not particularly limited. By using the analysis sensor of the present invention, the slgA can be detected by, for example, causing the nucleic acid molecule to bind to the slgA, as described above.

10 **[0068]** The analysis sensor of the present invention may be configured so that, for example, it further includes a carrier, and the nucleic acid molecule is disposed on the carrier. Preferably, the nucleic acid molecule is immobilized on the carrier. The immobilization of the nucleic acid molecule on the carrier is as described above, for example. The method for using the analysis sensor of the present invention is not particularly limited, and the descriptions of the nucleic acid molecule and the analysis method of the present invention can be incorporated in the description of the analysis sensor of the present invention by reference.

(3) Analysis method

20 **[0069]** As mentioned above, the analysis method of the present invention is a method including the step of: causing a specimen and a nucleic acid molecule to come into contact with each other to detect a secretory immunoglobulin A (slgA) in the specimen, wherein the nucleic acid molecule is the slgA-binding nucleic acid molecule of the present invention, and in the detection step, the nucleic acid molecule is caused to bind to the slgA in the specimen, and the slgA in the specimen is detected by detecting the binding. The analysis method of the present invention is characterized in that it uses the nucleic acid molecule of the present invention, and other steps, conditions, etc. are not particularly limited. In the analysis method of the present invention, the slgA analysis sensor of the present invention may be used as the nucleic acid molecule of the present invention.

25 **[0070]** The nucleic acid molecule of the present invention specifically binds to slgA. Thus, of the present invention, it is possible to specifically detect slgA in a specimen by detecting the binding between the slgA and the nucleic acid molecule, for example. Specifically, since the present invention can analyze the presence or absence or the amount of slgA in a specimen, for example, it can be said that the present invention also can perform qualitative or quantitative analysis of the slgA.

30 **[0071]** In the present invention, the specimen is not particularly limited. Examples of the specimen include saliva, urine, plasma, and serum.

35 **[0072]** The specimen may be a liquid specimen or a solid specimen, for example. The specimen preferably is a liquid specimen from the viewpoint of ease of handling because the liquid specimen can be brought into contact with the nucleic acid molecule more easily, for example. In the case of the solid specimen, a liquid mixture, a liquid extract, a solution, or the like of the solid specimen prepared using a solvent may be used, for example. The solvent is not particularly limited, and may be water, physiological saline, or a buffer solution, for example.

40 **[0073]** The above-described detection step includes, for example: a contact step of causing the specimen and the nucleic acid molecule to come into contact with each other to cause the nucleic acid molecule to bind to the slgA in the specimen; and a binding detection step of detecting the binding between the slgA and the nucleic acid molecule. The detection step may further include, for example, an analysis step of analyzing the presence or absence or the amount of the slgA in the specimen on the basis of the result obtained in the binding detection step.

45 **[0074]** In the contact step, the method for causing the specimen and the nucleic acid molecule to come into contact with each other is not particularly limited. The contact between the specimen and the nucleic acid molecule preferably is achieved in a liquid, for example. The liquid is not particularly limited, and may be, for example, water, physiological saline, or a buffer solution.

50 **[0075]** In the contact step, the conditions under which the contact between the specimen and the nucleic acid molecule is caused are not particularly limited. The contact temperature is, for example, 4°C to 37°C, or 18°C to 25°C, and the contact time is, for example, 10 to 120 minutes or 30 to 60 minutes.

55 **[0076]** In the contact step, the nucleic acid molecule may be an immobilized nucleic acid molecule immobilized on a carrier or an unimmobilized nucleic acid molecule in a free state, for example. In the latter case, the nucleic acid molecule is brought into contact with the specimen in a container, for example. The nucleic acid molecule preferably is the immobilized nucleic acid molecule from the viewpoint of favorable handleability, for example. The carrier is not particularly limited, and may be, for example, a substrate, beads, or a container. The container may be a microplate or a tube, for example. The immobilization of the nucleic acid molecule is as described above, for example.

**[0077]** The binding detection step is the step of detecting the binding between the slgA in the specimen and the nucleic acid molecule, as described above. By detecting the presence or absence of the binding between the slgA and the

nucleic acid molecule, it is possible to analyze the presence or absence of the sIgA in the specimen (qualitative analysis), for example. Also, by detecting the degree of the binding (the binding amount) between the sIgA and the nucleic acid molecule, it is possible to analyze the amount of the sIgA in the specimen (quantitative analysis), for example.

5 **[0078]** In the case where the binding between the sIgA and the nucleic acid molecule cannot be detected, it can be determined that no sIgA is present in the specimen. In the case where the binding is detected, it can be determined that the sIgA is present in the specimen.

10 **[0079]** The method for analyzing the binding between the sIgA and the nucleic acid molecule is not particularly limited. A conventionally known method for detecting the binding between substances may be employed as the method, for example, and specific examples of the method include the above-described SPR. Detection of the binding may be detection of a complex of the sIgA and the nucleic acid molecule, for example.

#### (4) Detection kit

15 **[0080]** A detection kit of the present invention is characterized in that it includes the sIgA-binding nucleic acid molecule of the present invention. It is only required that the detection kit of the present invention includes the nucleic acid molecule of the present invention, and other configurations are by no means limited. By using the detection kit of the present invention, it is possible to perform the detection and the like of the sIgA as mentioned above, for example.

20 **[0081]** The detection kit of the present invention may include the sensor of the present invention as the nucleic acid molecule of the present invention, for example. The detection kit of the present invention further may include any component(s) in addition to the nucleic acid molecule of the present invention, for example. Examples of the component include the above-described carrier, a buffer solution, and instructions for use.

#### Examples

25 **[0082]** Next, examples of the present invention are described below. It is to be noted, however, that the present invention is by no means limited by the following examples. Commercially available reagents in the examples were used in accordance with their protocols, unless otherwise stated.


#### [Example 1]

30 **[0083]** MK4 was prepared by the following synthesis examples.

35 **[0084]** Electrospray ionization mass spectrometry (ESI-MS) was performed using a mass spectrometer (API2000, vendor: Applied Biosystems) in positive or negative ion mode. <sup>1</sup>H NMR spectra were obtained using a nuclear magnetic resonance instrument (JNM-ECS400, manufactured by JEOL). Chemical shifts are expressed as relative  $\delta$  (ppm) to the internal standard, tetramethylsilane (Me<sub>4</sub>Si). Ion-exchange chromatography was performed using a chromatographic system (ECONO system, manufactured by Bio-Rad). In the ion-exchange chromatography, a glass column ( $\phi 25 \times 500$  mm) packed with diethylaminoethyl (DEAE) A-25-Sephadex (manufactured by Amershambiosciences) was used.

#### (Synthesis Example 1) Synthesis of MK1

40 **[0085]**



Scheme 1

25 **[0086]** AZ6 (290 mg,  $9.06 \times 10^{-4}$  mol) was dried in vacuo and dissolved in dry-DMF (N,N-dimethylformamide, 3 mL). To this solution, HOBt·H<sub>2</sub>O (1-hydroxybenzotriazole monohydrate, 176 mg,  $1.15 \times 10^{-5}$  mol, 1.2 eq.), PyBOP® (hexafluorophosphoric acid (benzotriazole-1-yloxy)tripyrrolidinophosphonium, 579 mg,  $1.15 \times 10^{-5}$  mol, 1.2 eq.), and DIPEA (N,N-diisopropylethylamine, 4.6 mL,  $2.72 \times 10^{-2}$  mol, 30 eq.) were added, and NK1 (493 mg,  $9.48 \times 10^{-4}$  mol, 1.1 eq.) dissolved in dry-DMF (1 mL) was further added and stirred. After 40 minutes from the initiation of the stirring, the solvent was distilled off under reduced pressure, and a residue was dissolved in water, and a precipitate was collected by suction

30 filtration. The filtrate was roughly purified by reversed-phase column chromatography, to give MK1.

Physical properties of MK1 are shown below.

Yield amount: 261 mg, Yield: 60%


ESI-MS (positive ion mode) m/z, found = 481.2, calculated for [(M+H)+] = 481.2

Found = 503.1, calculated for [(M+Na)+] = 503.2

35 <sup>1</sup>HNMR (400 MHz, DMSO-d<sub>6</sub>) δ 8.22 (1H, m), 8.11 (1H, s), 8.10 (1H, s), 7.87 (1H, s), 7.63 (1H, d), 6.52 (1H, q), 6.35 (1H, d), 5.27 (1H, s), 3.82 (1H, m), 2.18 (1H, m)

(Synthesis Example 2) Synthesis of MK2

40 **[0087]**



Scheme 2


**[0088]** MK1 (108 mg,  $2.25 \times 10^{-4}$  mol) was dried in vacuo, and the atmosphere was replaced with Argon (Ar). Subsequently, azeotropy between the MK1 and dry-DMF was caused twice (the first time: 40 mL, the second time: 4 mL), and azeotropy between the MK1 and dry-MeCN (acetonitrile) was caused three times (the first time: 9 mL, the second time: 5 mL, the third time: 5 mL). The resultant azeotrope was suspended in dry-Trimethyl phosphate (6 mL), and thereafter, dry-Tributyl amine (130  $\mu$ L,  $5.44 \times 10^{-4}$  mol, 2.5 eq.) was added thereto. Then, phosphoryl chloride (42  $\mu$ L,  $4.50 \times 10^{-4}$  mol, 2 eq.) was added and stirred under ice cooling. After 40 minutes from the initiation of the stirring, dry-Tributyl amine (250  $\mu$ L,  $1.05 \times 10^{-3}$  mol, 5 eq.) and Phosphoryl chloride (84  $\mu$ L,  $4.50 \times 10^{-4}$  mol, 4 eq.) were again added and stirred under ice cooling for 1 hour. After the stirring, a cooled 1 mol/L TEAB (Triethylammonium bicarbonate) buffer (5 mL) was added, stirred for 5 minutes, and quenched. Then, the solvent was distilled off under reduced pressure, crystallization was performed in Ether, and suction filtration was performed to obtain a yellow solid. The yellow solid was dissolved in water, purified by anion-exchange chromatography, and freeze-dried, to give MK2. Physical properties of MK2 are shown below.

Yield amount: 30.0  $\mu$ mol, Yield: 13.4%

ESI-MS (negative ion mode) m/z, found = 559.1, calculated for [(M-H)-] = 559.2

(Synthesis Example 3) Synthesis of MK3

**[0089]**




Scheme 3

**[0090]** MK2 (30.03  $\mu$ mol) was dried in vacuo, and azeotropy between the MK2 and dry-Pyridine (10 mL) was performed three times, and the azeotrope was dried in vacuo overnight. After the drying, the atmosphere was replaced with Ar, and the MK2 was dissolved in dry-DMF (2 mL) and dry-TEA (triethylamine, 28  $\mu$ L,  $1.98 \times 10^{-4}$  mol, 6.6 eq.). Further, Imidazole (16 mg,  $14.02 \times 10^{-4}$  mol, 4 eq.), 2,2'-Dithiodipyridine (17 mg,  $7.72 \times 10^{-4}$  mol, 1.6 eq.), and Triphenylphosphine (20 mg,  $7.63 \times 10^{-4}$  mol, 1.6 eq.) were added and stirred at room temperature. After 6.5 hours from the initiation of the stirring, the resultant reaction solution was added to a solution of Sodium perchlorate (39 mg,  $3.19 \times 10^{-4}$  mol, 10 eq.) in dry-Acetone (18 mL), dry Ether (27 mL), and dry-TEA (2 mL), and allowed to stand at 4°C for 30 minutes. The precipitate was decanted 5 times with dry-Ether (12 mL) and was thereafter dried in vacuo, to give MK3 as a crude.

Theoretical yield amount: 30.03  $\mu$ mol

(Synthesis Example 4) Synthesis of MK4

**[0091]**



Scheme 4

20 **[0092]** MK3 (30.03  $\mu\text{mol}$ ) was dried in vacuo, the atmosphere was replaced with Ar, and then, azeotropy between the MK3 and dry-Pyridine (5 mL) was caused twice, and the azeotrope was then suspended in dry-DMF (1 mL). Further, dry-n-Tributylamine (30  $\mu\text{L}$ ,  $1.25 \times 10^{-4}$  mol, 4 eq.) and 0.5 mol/L n-Tributylamine pyrophosphate in DMF (310  $\mu\text{L}$ ,  $1.53 \times 10^{-4}$  mol, 5 eq.) were added to the suspension and then stirred at room temperature. After 6.5 hours from the initiation of the stirring, a 1 mol/L TEAB buffer (5 mL) was added and stirred for 30 minutes, and then the solvent was distilled off under reduced pressure. Water was added, an aqueous layer was separated with Ether twice, purified by anion-exchange column chromatography, and freeze-dried, to give MK4. Physical properties of MK4 are shown below.

25 Yield amount: 3.33  $\mu\text{mol}$ , Yield: 11.1%  
ESI-MS (negative ion mode) m/z, found = 719.0, calculated for [(M-H)-] = 719.1


[Example 2]

30 **[0093]** NG7 was prepared by the following synthesis example.

35 **[0094]** Electrospray ionization mass spectrometry (ESI-MS) was performed using a mass spectrometer (API2000, vendor: Applied Biosystems) in positive or negative ion mode.  $^1\text{H}$  NMR spectra were obtained using a nuclear magnetic resonance instrument (JNM-ECS400, manufactured by JEOL). Chemical shifts are expressed as relative  $\delta$  (ppm) to the internal standard, tetramethylsilane ( $\text{Me}_4\text{Si}$ ). Ion-exchange chromatography was performed using a chromatographic system (ECONO system, manufactured by Bio-Rad). In the ion-exchange chromatography, a glass column ( $\varnothing 25 \times 500$  mm) packed with diethylaminoethyl (DEAE) A-25-Sephadex (manufactured by Amershambiosciences) was used.

(Synthesis Example 1) Synthesis of NH1

40 **[0095]**



Scheme 5

55 **[0096]**  $\text{CHCl}_3$  (20 mL) containing tert-butyl dicarbonate (5 g, 22.9 mmol, 0.2 eq.) dissolved therein was added dropwise to  $\text{CHCl}_3$  (120 mL) containing ethylenediamine (7 mL, 105 mmol, 1 eq.) dissolved therein while stirring. After 24 hours from the addition, the solution was subjected to suction filtration, and the solvent was distilled off under reduced pressure to give NH1. Physical properties of NH1 are shown below.

EP 3 514 237 A1


Yield amount: 3.573 g, Yield: 97.4%

ESI-MS (positive ion mode) m/z, found= 161.4, calculated for [(M+H)+] = 161.1

<sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>) δ3.13 (2 H, q) 2.76 (2H, t) 1.41 (9 H, s)

5 (Synthesis Example 2) Synthesis of NG1

[0097]



2,6-Dichloropurine

NG1

20 Exact Mass: 187.97  
Molecular Weight: 189.00

Exact Mass: 170.00  
Molecular Weight: 170.56

25 Scheme 6

[0098] The atmosphere of 2,6-Dichloropurine (1000 mg,  $5.29 \times 10^{-3}$  mol, 10. eq.) was replaced with Ar (argon), and the 2,6-Dichloropurine was dissolved in an aqueous sodium hydroxide solution (10.6 mL,  $2.12 \times 10^{-2}$  mol, 2N) and refluxed at 90°C, to cause a reaction. After the reaction, the temperature was returned to room temperature, and the solution was subjected to suction filtration. The obtained filtrate was collected, dissolved in a minimal amount of water, the pH was adjusted to 3 to 4, and the precipitated filtrate was collected by suction filtration to give NG1. The physical properties of NG1 are shown below.

Yield amount: 720 mg, Yield: 79%

ESI-MS (positive ion mode) m/z, found = 171.0, calculated for [(M+H)+] = 171.0


found = 193.1, calculated for [(M+Na)+] = 193.0

found = 209.1, calculated for [(M+K)+] = 209.0

ESI-MS (negative ion mode) m/z, found = 169.0, calculated for [(M-H)-] = 169.0 <sup>1</sup>HNMR (400 MHz, DMSO-d<sub>6</sub>) δ8.29 (1H, s)

(Synthesis Example 3) Synthesis of NG2

40 [0099]



Exact Mass: 170.00  
Molecular Weight: 170.56

Exact Mass: 294.14  
Molecular Weight: 294.32

55 Scheme 7

[0100] Each of NG1 (870 mg,  $5.10 \times 10^{-3}$  mol) and NH1 (3.281 g,  $2.05 \times 10^{-2}$  mol, 4 eq.) was dried in vacuo, and the atmospheres of the NG1 and the NH1 were replaced with Ar. The NG1 was suspended in Methoxyethanol (5 mL), and the NH1 was dissolved in Methoxyethanol (1 mL). The obtained NH1 solution was transferred to a recovery flask containing the NG1, which was then refluxed at 130°C, to cause a reaction. After the reaction, the temperature was

EP 3 514 237 A1

returned to room temperature, and the solvent in the solution was distilled off under reduced pressure. The solution was further subjected to redeposition with chloroform, and a deposit was filtered by suction, and a filtrate was collected, to give NG2. Physical properties of NG2 are shown below.

Yield amount: 1.117 mg, Yield 74%.

ESI-MS (positive ion mode) m/z, found = 171.0, calculated for [(M+H)+] = 171.0,

found = 193.1, calculated for [(M+Na)+] = 193.0,


found = 209.1, calculated for [(M+K)+] = 209.0,

ESI-MS (negative ion mode) m/z, found = 169.0, calculated for [(M-H)-] = 518.0

<sup>1</sup>HNMR (400 MHz, CD<sub>3</sub>OD) δ7.73 (1H, s), 3.45 (2H, m), 3.30 (2H, s), 1.39 (9H, s)

(Synthesis Example 4) Synthesis of NG3

[0101]



**NG2**

Exact Mass: 294.14  
Molecular Weight: 294.32

**NG3**

Exact Mass: 194.09  
Molecular Weight: 194.20

Scheme 8

[0102] The NG2 (500 mg,  $1.70 \times 10^{-3}$  mol) was suspended in methanol (3mL), Trifluoroacetate (15 mL) was added and stirred at room temperature, to cause a reaction. After the reaction, the solvent in the mixture was distilled off under reduced pressure, suspended in Ether, and subjected to suction filtration, and the filtrate was collected, to give NG3. The physical properties of NG3 are shown below.

Yield amount: 467 mg, Yield: 89.1%

ESI-MS (positive ion mode) m/z, found = 195.1, calculated for [(M+H)+] = 195.1,


found = 217.2, calculated for [(M+Na)+] = 217.1,

found = 233.0, calculated for [(M+K)+] = 233.1

<sup>1</sup>HNMR (400 MHz, D<sub>2</sub>O) δ7.83 (1H, s), 3.55 (2H, t), 3.11 (2H, t)

(Synthesis Example 5) Synthesis of NG4

[0103]



**(E)-5-(2-Carboxyrinyl)-  
2'-deoxyuridine**

Exact Mass: 298.08  
Molecular Weight: 298.25

**NG4**

Exact Mass: 474.16  
Molecular Weight: 474.43

Scheme 9

EP 3 514 237 A1

**[0104]** (E)-5-(2-Carboxyrinyl)-2'-deoxyuridine (101 mg,  $3.39 \times 10^{-4}$  mol) and a stirring bar were placed in a recovery flask A. The NG3 (171 mg,  $4.12 \times 10^{-4}$  mol, 1.2 eq.) and a stirring bar were placed in a recovery flask B. The recovery flasks A and B were then dried in vacuo. Subsequently, the inside of the recovery flask A was replaced with Ar, and HOBT·H<sub>2</sub>O (68 mg,  $4.44 \times 10^{-4}$  mol, 1.3 eq.) and PyBOP® (hexafluorophosphoric acid (benzotriazole-1-yloxy)tripyrrolidinophosphonium, 229 mg,  $4.40 \times 10^{-4}$  mol, 1.3 eq.) were then added, and the resultant mixture was dissolved in dry-DMF (N,N-dimethylformamide, 1 mL). Further, the inside of the recovery flask B was replaced with Ar, the NG3 was dissolved in DRY-dmf (0.5 mL). DIPEA (N,N-diisopropylethylamine, recovery flask A: 0.79 mL,  $4.51 \times 10^{-3}$  mol, 13.3 eq.; recovery flask B: 0.79 mL,  $4.51 \times 10^{-3}$  mol, 6.7 eq.) was added to each of the recovery flasks A and B, thereafter, the contents of the recovery flask B were rapidly added to the recovery flask A, stirred at room temperature, to cause a reaction. After the reaction, the solvent in the solution was distilled off under reduced pressure, and the resultant was suspended in CDCl<sub>3</sub> (deuterated chloroform). The obtained suspension was further sonicated and subjected to filtration. The obtained filtrate was recovered, suspended in MeOH, and sonicated, and then subjected to filtration. The obtained filtrate was collected, to give NG4. The physical properties of NG4 are shown below.

Yield amount: 147 mg, Yield: 91%

ESI-MS (positive ion mode) m/z, found = 475.1, calculated for [(M+H)+] = 475.2,


found = 497.2, calculated for [(M+Na)+] = 497.2,

ESI-MS (negative ion mode) m/z, found = 473.1, calculated for [(M-H)-] = 473.2

<sup>1</sup>HNMR (400 MHz, DMSO-d<sub>6</sub>) δ8.27 (1H, s), 8.20 (1H, s), 7.10 (1H, s), 7.05 (1H, s), 6.13 (1H, t), 5.25 (1H, d), 5.16 (1H, m), 4.09 (1H, m), 3.79 (1H, m), 3.60 (2H, m), 3.16 (2H, d), 2.14 (2H, m)

(Synthesis Example 6) Synthesis ofNG5

**[0105]**



Scheme 10


**[0106]** The NG4 (101 mg,  $2.13 \times 10^{-4}$  mol) was dried in vacuo, and the azeotropy between the NG4 and dry-Pyridine (30 mL) was then performed twice under Ar atmosphere. Subsequently, the azeotrope was suspended in dry-Trimethyl phosphate (21 mg), and Phosphoryl chloride (400 μL,  $4.29 \times 10^{-3}$  mol, 20 eq.) was added under ice bath to the suspension and was then stirred for 2.5 hours. After the stirring, Phosphoryl chloride (200 μL,  $2.15 \times 10^{-3}$  mol, 10 eq.) was added and was then stirred for 8.5 hours. After the stirring, cold water (10ml) was added to quench, which was then stirred for 10 minutes. TEA (triethylamine, 2.7 mL,  $1.94 \times 10^{-2}$  mol, 90 eq.) was then added, which was then stirred for 15 minutes. The solvent was then distilled off under reduced pressure, a crystallization was performed by Ether and MeCN (acetonitrile), and the obtained crystal was filtered, to collect a yellow precipitate. The obtained yellow precipitate was dissolved in water, purified by anion-exchange column chromatography, and freeze-dried, to give NG5. Physical properties of NG5 are shown below.

Yield amount: 41.49 μmol, Yield: 19.5%

ESI-MS (negative ion mode) m/z, found = 553.1, calculated for [(M-H)-] = 553.1

(Synthesis Example 7) Synthesis ofNG6

**[0107]**



## Scheme 11


[0108] The NG5 (78.65  $\mu\text{mol}$ ) was dried in vacuo, azeotropy between the NG5 and dry-Pyridine (5 mL) was thereafter caused three times, and the azeotrope was then further dried in vacuo overnight. After the drying, the atmosphere of this was replaced with Ar, this was then dissolved in dry-DMF (2 mL) and dry-TEA (72  $\mu\text{L}$ ,  $5.19 \times 10^{-4}$  mol, 4 eq.), and Imidazole (24 mg,  $3.53 \times 10^{-4}$  mol, 4 eq.), 2,2'-Dithiodipyridine (29 mg,  $1.32 \times 10^{-4}$  mol, 1.6 eq.), and Triphenylphosphine (36 mg,  $1.37 \times 10^{-4}$  mol, 1.6 eq.) were further added and stirred at room temperature. After 8 hours from the initiation of the stirring, the resultant reaction solution was added to a solution of Sodium perchlorate (97 mg,  $7.92 \times 10^{-4}$  mol, 10 eq.) in dry-Acetone (18 mL), dry Ether (27 mL), and dry-TEA (2 mL), and allowed to stand at 4°C for 30 minutes. The precipitate was decanted 5 times with dry-Ether (12 mL) and was thereafter dried in vacuo, to give NG6 as a crude. Theoretical yield amount: 78.65  $\mu\text{mol}$

15

20

(Synthesis Example 8) Synthesis of NG7

25 [0109]



## Scheme 12

[0110] The atmosphere of the vacuum-dried NG6 (78.65  $\mu\text{mol}$ ) was replaced with Ar, azeotropy between the NG6 and dry-Pyridine (5 mL) was then caused twice, and the azeotrope was suspended in dry-DMF (1 mL). Further, dry-n-Tributylamine (75  $\mu\text{L}$ ,  $3.15 \times 10^{-4}$  mol, 4 eq.) and 0.5 mol/L n-Tributylamine pyrophosphate in DMF (0.8  $\mu\text{L}$ ,  $3.93 \times 10^{-4}$  mol, 5 eq.) were added to the suspension and then stirred at room temperature. After 9 hours from the initiation of the stirring, a 1 mol/L TEAB (Triethylammonium bicarbonate) buffer (5 mL) was added and stirred for 30 minutes, and then the solvent was distilled off under reduced pressure. Water was added, an aqueous layer was separated with Ether twice, purified by anion-exchange column chromatography, and freeze-dried, to give NG7. Physical properties of NG7 are shown below.

40

45

Yield amount: 19.55  $\mu\text{mol}$ , Yield: 24.9%

ESI-MS (negative ion mode) m/z, found = 712.9, calculated for [(M-H)-] = 713.1

[Example 3] The present example examined the binding ability and a kinetic parameter of each of aptamers represented by SEQ ID NOs: 1 to 21 to slgA by SPR.

50

(1) Aptamers

[0111] As aptamers of the examples, the following polynucleotides were synthesized. In the aptamers of SEQ ID NOs: 1 to 4 (hereinafter also referred to as "MK4 aptamers"), nucleotide residues containing underlined adenines in the following Table 3 are nucleotide residues represented by the chemical formula (1). In the aptamers of SEQ ID NOs: 8 to 12 and 16 to 21 (hereinafter also referred to as "KS9 aptamers"), nucleotide residues containing underlined thymines in the following Table 3 are nucleotide residues represented by the chemical formula (2). In the aptamers of SEQ ID NOs: 5

55

## EP 3 514 237 A1

to 7 and 13 to 15 (hereinafter also referred to as "NG7 aptamers", nucleotide residues containing underlined thymines in the following Table 3 are nucleotide residues represented by the chemical formula (3).

5

10

15

20

25

30

35

40

45

50

55

[Table 3]

SEQ ID NO:	Modified base	Base sequence
1	MK4	5'-GGTTGGACGCAATCTCCCTAATCTACTACGATATCCAGATGGGAAGTACCCTGAAACTACAATGGCGGGCTTATC-3'
2	MK4	5'-GGTTGGACGCAATCTCCCTAATCAGATGATATCGAGATCGGAAGCCGACCCGATGAAACTACAATGGCGGGCTTATC-3'
3	MK4	5'-GGTTGGACGCAATCTCCCTAATCAAGCCACGGAGAGTCCGAGGTGACCATTAAAGCAGGAAACTACAATGGCGGGCTTATC-3'
4	MK4	5'-GGTTGGACGCAATCTCCCTAATCGATCTAGATGGTCTCGGGTATGGCTAGATAGAAACTACAATGGCGGGCTTATC-3'
5	NG7	5'-GGTTGGACGCAATCTCCCTAATCTGCTGATGTTGTTTCAAAATTAGCCGCAGAAACTACAATGGCGGGCTTATC-3'
6	NG7	5'-GGTTGGACGCAATCTCCCTAATCTAAATAGATTTACACAGTGGATCCCTTACAGAGAAACTACAATGGCGGGCTTATC-3'
7	NG7	5'-GGTTGGACGCAATCTCCCTAATCAGACAATAATTAGAGTGTACCACCTGTGATGAAACTACAATGGCGGGCTTATC-3'
8	KS9	5'-GGTTGGACGCAATCTCCCTAATCGTATATCAAGCAGATGTGTTCACTTGGGAGAAACTACAATGGCGGGCTTATC-3'
9	KS9	5'-GGTTGGACGCAATCTCCCTAATCAAAGATATGCTAAGATAGATGTTGGCTTGAAC TACAATGGCGGGCTTATC-3'
10	KS9	5'-GGTTGGACGCAATCTCCCTAATCACCTGTACTGGTTATTATGCCTGCCAACATGAAACTACAATGGCGGGCTTATC-3'
11	KS9	5'-GGTTGGACGCAATCTCCCTAATCTTTATACGATGGACTTAGGCTTGTATAGAAACTACAATGGCGGGCTTATC-3'
12	KS9	5'-GGTTGGACGCAATCTCCCTAATCTCTATCTGTTTTATCAATTGTAGCAAGTTATGAAACTACAATGGCGGGCTTATC-3'
13	NG7	5'-GGTTGGACGCAATCTCCCTAATCTGCTGATGTTTGTATTTCAAAATTAGCCGCAG-3'
14	NG7	5'-GCAATCTCCCTAATCTGCTGATGTTTGTATTTCAAAATTAGCCGCAG-3'
15	NG7	5'-GCAATCTCCCTAATCTGCTGATGTTTGTATTTCAAAATTAGC-3'
16	KS9	5'-GGTTGGACGCAATCTCCCTAATCGTATATCAAGCAGATGTGTTCACTTGGGGAG-3'
17	KS9	5'-GCAATCTCCCTAATCGTATATCAAGCAGATGTGTTCACTTGGGGAG-3'
18	KS9	5'-GGTTGGACGCAATCTCCCTAATCAAAGATATGCTAAGATAGATAGTTTGGCTTG-3'
19	KS9	5'-GCAATCTCCCTAATCAAAGATATGCTAAGATAGATTGGCTTG-3'
20	KS9	5'-GGTTGGACGCAATCTCCCTAATCTTTATACGATGGACTTAGGCTTGTATAGAAAC-3'
21	KS9	5'-GCAATCTCCCTAATCTTTATACGATGGACTTAGGCTTGTATAGAAAC-3'

## EP 3 514 237 A1

**[0112]** To the 3' end of each of the MK4 aptamers, 20-mer polydeoxythymine (poly[dT]) was added. Each of the thus-obtained poly(dT)-added aptamers was used in SPR to be described below. To the 3' end of each of the KS9 aptamers and the NG7 aptamers, 20-mer polydeoxyadenine (poly[dA]) was added. Each of the thus-obtained poly(dA)-added aptamers was used in SPR to be described below.

### (2) Specimen

**[0113]** Commercially available human sIgA (IgA (Secretory), Human, manufactured by MP Biomedicals, LLC-Cappel Products, Catalog No.: #55905) was used as a specimen in the following tests.

### (3) Analysis of binding ability by SPR

**[0114]** The analysis of the binding ability was carried out using a ProteON XPR36 (BioRad) in accordance with its instructions for use.

**[0115]** First, as a sensor chip designed specifically for the ProteON, a streptavidin-immobilized chip (trade name: ProteON NLC Sensor Chip, BioRad) was set in the ProteON XPR36. Biotinylated poly(dA) at 5  $\mu$ mol/L was injected to a flow cell of the sensor chip using ultrapure water (DDW), and the binding was allowed to proceed until the signal intensity (RU: Resonance Unit) reached about 900 RU. The biotinylated poly(dA) was prepared by biotinylating the 5' end of 20-mer deoxyadenosine. Then, the poly(dT)-added MK4 aptamer at 200 nmol/L was injected to the flow cell of the chip using an SPR buffer at a flow rate of 25  $\mu$ L/min for 80 seconds, and the binding was allowed to proceed until the signal intensity reached about 800 RU. This result, which corresponds to the signal indicating the amount of the aptamer immobilized on the sensor chip, is referred to as an "aptamer immobilization measured value (A)". Subsequently, the specimen was injected using the SPR buffer at a flow rate of 50  $\mu$ L/min for 120 seconds, followed by washing performed by flowing the SPR buffer under the same conditions for 300 seconds. The concentration of the human sIgA in the specimen was set to 400 nmol/L. Signal intensity measurement was performed concurrently with the injection of the specimen and the washing with the SPR buffer. With 0 seconds being the start of the injection, the mean value of signal intensities from 115 seconds to 125 seconds was determined. This result, which corresponds to the signal indicating the binding amount between the aptamer and the protein, is referred to as a "protein binding measured value (B)". Then, the value (B/A) obtained by dividing the protein binding measured value (B) by the aptamer immobilization measured value (A) was determined as a relative value (Relative Unit). The KS9 aptamer and the NG7 aptamer were subjected to the measurement in the same manner as described above except that biotinylated poly dT prepared by biotinylating the 5' end of 20-mer deoxythymidine is used as a substitute for the biotinylated poly dA, and the KS9 aptamer or the NG7 aptamer was used as a substitute for the MK4 aptamer. Further, in Comparative Examples 3-1 and 3-2, the signal intensity was measured in the same manner as described above except that a negative-control nucleic acid molecule (SEQ ID NO: 22) exhibiting no binding properties to sIgA is used as a substitute for the MK4 aptamer in Comparative Example 3-1, and a specimen containing BSA (Bovine Serum Albumin, manufactured by SIGMA, Catalog No.: #A7906) was used as a substitute for the human sIgA in Comparative Example 3-2.

**[0116]** Negative-control nucleic acid molecules (N30-0 pool) 5'-GGTAACGCCAGTCTAGGTCATTTG-(N)<sub>30</sub>-GT-TACGGGAGCCTGCACTTAATG-3' (SEQ ID NO: 22)

**[0117]** The composition of the SPR buffer was as follows: 40 mmol/L HEPES, 125 mmol/L NaCl, 5 mmol/L KCl, 1 mmol/L MgCl<sub>2</sub>, and 0.01% Tween® 20. The pH of the SPR buffer was set to 7.4.

**[0118]** FIGs. 1A to 1F show the results of binding between each aptamer and sIgA. FIGs. 1A to 1F are graphs showing the binding ability of the aptamers to sIgA. In FIG. 1, the horizontal axis indicates the elapsed time after injection of the specimen, and the vertical axis indicates the relative unit (RU) of binding affinity. As shown in FIGs. 1A to 1F, all of the aptamers bind to sIgA.

**[0119]** Then, FIGs. 2A to 2D show values (B/A) each obtained by dividing the protein binding measured value (B) by the aptamer immobilization measured value (A) as the results of relative values (relative units). FIGs. 2A to 2D are graphs showing the relative units (RU) of the binding amounts of the respective aptamers to sIgA. In FIG. 2, the horizontal axis indicates the type of the aptamer, and the vertical axis indicates the relative value. As shown in FIGs. 2A to 2D, binding was not found in Comparative Example 3-2 using BSA. Moreover, binding to sIgA was not found in Comparative Example 3-1 using the negative control nucleic acid molecule. In contrast, all of the aptamers were bound to sIgA. In particular, nucleic acid molecules of SEQ ID NOs: 15 and 21 exhibited excellent binding properties.

### (4) Measurement of dissociation constant

**[0120]** The relative values (RU) of the binding amounts were measured in the same manner as described in the item (3) above except that the concentration of sIgA in the respective specimens were 12.5, 25, 50, 100, or 200 nmol/L. Then, based on the relative values of the binding amounts, the dissociation constants of the respective sIgA-binding nucleic

## EP 3 514 237 A1

acid molecules and the slgA were calculated. The results obtained are shown in Table 4 below. As shown in Table 4 below, the dissociation constants of all of the aptamers were 37.7 nM or less. In particular, the nucleic acid molecules of SEQ ID NOs: 2, 3, 9, 11, 15, 19, and 21 were found to have dissociation constants of 8 nM or less and to have excellent binding abilities to slgA.

[Table 4]

SEQ ID NO:	Dissociation constant(Kd (nM))
1	8.6
2	7.6
3	7.6
4	17.4
5	11.8
6	11.6
7	37.7
8	10
9	4.8
10	30.2
11	1.3
12	9
14	10
15	2.59
17	12.9
19	8
21	2.1

### (5) Determination of cross-reactivity

**[0121]** The relative values of the binding amounts were determined in the same manner as in the item (3) above except that the aptamers of SEQ ID NOs: 3, 5, and 9 were used, and a specimen containing slgA, human IgG-Fc (Comparative Example 3-3, manufactured by BETHYL, Catalog No.: P-80-104), unlabeled human IgG (Comparative Example 3-4, manufactured by BECKMAN COULTER, Catalog No.: 731696), unlabeled human IgG-Fc (Comparative Example 3-5, manufactured by BECKMAN COULTER, Catalog No.: 731703), or human IgG1 $\kappa$  (Comparative Example 3-6, manufactured by Southern Biotech, Catalog No.: 0151K-01) to have 400 nmol/L was used as a specimen.

**[0122]** The results obtained are shown in FIG. 3. FIG. 3 is a graph showing the relative values of the binding amounts. In FIG. 3, the horizontal axis indicates the type of the specimen, and the vertical axis indicates the relative value (RU) of the binding amount. As shown in Table 3 below, none of the aptamers is bound to immunoglobulins other than slgA. From these results, it was found that the nucleic acid molecules of the present invention are specific to slgA.

[Example 4]

**[0123]** The present example examined the binding ability of the aptamers of SEQ ID NOs: 5, 9, and 11 to slgA by a pull-down assay using magnetic beads.

#### (1) Aptamer-bound beads

**[0124]** SA beads (Invitrogen Corporation, trade name: MyOne-SA C1), which are magnetic beads having streptavidin (SA) bound to their surfaces, were provided, and the aptamer of SEQ ID NO: 5, 9, or 11 was caused to bind to the SA beads to prepare aptamer-bound beads. More specifically, the aptamer-bound beads were prepared in the following manner. First, a complementary strand 100% complementary to the aptamer was prepared. On the other hand, a 5'

region sequence (SEQ ID NO: 23, 5'-GGATACCTTAACGCCGCTATTG-3') of the aptamer was provided, and the 5' end thereof was biotinylated to prepare a biotinylated primer. Then, amplification by PCR was performed using the biotinylated primer with the complementary strand as a template, whereby the aptamer with the 5' end thereof being biotinylated was synthesized. A double strand composed of the synthesized aptamer and the complementary strand was reacted with the SA beads, thereby causing biotin in the double strand to bind to avidin in the SA beads. Subsequently, by an alkali treatment of the complexes of the double strands and the SA beads with NaOH, each double strand was dissociated to remove the complementary strand. Through the above-described process, the aptamer-bound beads, which are the SA beads having the biotinylated aptamers bound thereto via biotin-avidin binding, were prepared.

## (2) Specimen

**[0125]** 5  $\mu$ g of human sIgA or Human saliva was used as a specimen in an experiment to be described below.

## (3) Pull-down assay

**[0126]** The aptamer-bound beads (final concentration: 10 mg/mL) and the specimen (final concentration of sIgA: 50  $\mu$ g/mL, final concentration of saliva: 90%) were mixed together in an SB1T buffer solution (40 mmol/L HEPES, 125 mmol/L NaCl, 5 mmol/L KCl, 1 mmol/L MgCl<sub>2</sub>, and 0.01% Tween® 20, pH 7.4). This reaction solution was allowed to react at room temperature for 30 minutes. The reaction solution was centrifuged to collect the beads, and the beads were subjected to centrifugal washing with the SB1T buffer solution three times. In the case where the aptamer has bound to sIgA, the beads carry the sIgA bound thereto via the aptamer. Thus, the sIgA was released from the beads by mixing the beads in an SDS buffer solution and heat-treating the SDS buffer solution at 95°C for 10 minutes. Then, the beads were removed from the SDS buffer solution after the heat treatment, and the SDS buffer solution was subjected to SDS-PAGE using a PAGEL (C520L, ATTO Corporation). As a buffer for electrophoresis, the SDS buffer was used. The composition of the SDS buffer was as follows: 25 mmol/L Tris, 192 mmol/L glycine, and 0.1% SDS.

**[0127]** Next, the gel after being subjected to the SDS-PAGE was stained using a GelCode Blue Stain Reagent (Thermo SCIENTIFIC). As a molecular-weight marker, a Bench Mark Protein Ladder (Invitrogen Corporation) was used. Further, as a control 1, SDS-PAGE and detection were carried out in the same manner, except that, instead of the aptamer-bound beads, the SA beads having the biotinylated primer bound thereto were used. Further, as a control 2, SDS-PAGE and detection were carried out with respect to the human sIgA.

**[0128]** The results obtained are shown in FIG. 4. FIGs. 4A and 4B are photographs showing the results of the SDS-PAGE with respect to the proteins released from the aptamer-bound beads. FIG. 4A shows the result obtained by using a specimen containing sIgA, and FIG. 4B shows the result obtained by using saliva. In FIGs 4A and 4B, the molecular weight is shown on the left side of the photograph, Lane M shows the molecular-weight marker (M), Lane 1 shows the result obtained when the aptamer-bound beads having the aptamer of SEQ ID NO: 5 bound thereto were used, Lane 2 shows the result obtained when the aptamer-bound beads having the aptamer of SEQ ID NO: 9 bound thereto were used, Lane 3 shows the result obtained when the aptamer-bound beads having the aptamer of SEQ ID NO: 11 bound thereto were used, Lane C1 shows the result obtained when the SA beads having the primer bound thereto were used, and Lane IgA shows the result of human sIgA.

**[0129]** As can be seen from FIGs. 4A and 4B, in Lanes 1 to 3 showing the result obtained when the aptamer-bound beads were used, the band was observed at the same site as in Lane IgA showing the result obtained when the sIgA was used (see the bands indicated with the arrows in FIGs. 4A and 4B). On the other hand, when the primer-bound beads were used, the band was not observed at the same site as when the sIgA was used.

**[0130]** From these results, it was found that the aptamer of the present invention exhibits binding properties to the human sIgA.

**[0131]** Although the present invention is described above with reference to embodiments and examples, the present invention is not limited thereto. Various modifications can be made within the scope of the present invention which can be understood by those skilled in the art.

**[0132]** The present application is based upon and claims the benefit of priority from Japanese patent application No. 2016-180892, filed on September 15, 2016, and the entire disclosure of which is incorporated herein its entirety by reference.

## Industrial Applicability

**[0133]** The sIgA-binding nucleic acid molecule of the present invention can bind to sIgA with the above-described dissociation constant. Thus, the sIgA-binding nucleic acid molecule of the present invention can detect sIgA in a specimen with high accuracy on the basis of the presence or absence of the binding with the sIgA, for example. Therefore, it can be said that the sIgA-binding nucleic acid molecule of the present invention is a very useful tool for the detection of sIgA

**EP 3 514 237 A1**

in the fields of preventive medicine, health care, diagnoses of infectious diseases, diagnoses of stress, and the like, for example.

[Sequence Listing] TF16064WO\_ST25.txt

5

10

15

20

25

30

35

40

45

50

55

EP 3 514 237 A1

SEQUENCE LISTING

<110> NEC Solution Innovators, Ltd.  
 National University Corporation Gunma University

5

<120> Nucleic acid molecule of biding secretory form immunoglobulin A  
 (sIgA), sensor of analyzing sIgA and method of analyzing sIgA

<130> 1010100054

10

<150> JP2016-180892  
 <151> 2016-09-15

<160> 23

15

<170> PatentIn version 3.5

<210> 1  
 <211> 78  
 <212> DNA  
 <213> Artificial Sequence

20

<220>  
 <223> Synthesized polynucleotide

<400> 1  
 ggtttgacg caatctcct aatctactac gatatccaga tgggaagtga ccgtgaaact 60  
 acaatgggcg ggcttatc 78

25

<210> 2  
 <211> 78  
 <212> DNA  
 <213> Artificial Sequence

30

<220>  
 <223> Synthesized polynucleotide

35

<400> 2  
 ggtttgacg caatctcct aatcagatga tatcgagatg cgaagcgacc gcatgaaact 60  
 acaatgggcg ggcttatc 78

40

<210> 3  
 <211> 80  
 <212> DNA  
 <213> Artificial Sequence

45

<220>  
 <223> Synthesized polynucleotide

<400> 3  
 ggtttgacg caatctcct aatcaagcca cggagagtcc gaggtgacca ttaagcagga 60  
 aactacaatg ggcgggctta 80

50

<210> 4  
 <211> 78  
 <212> DNA  
 <213> Artificial Sequence

55

EP 3 514 237 A1

<220>  
 <223> Synthesized polynucleotide  
  
 <400> 4  
 5 ggtttggacg caatctccct aatcgatcta gatggtctcg ggtatggcta gatagaaact 60  
 acaatgggcg ggcttatc 78  
  
 <210> 5  
 <211> 78  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 15 <223> Synthesized polynucleotide  
  
 <400> 5  
 ggtttggacg caatctccct aatctgctga tgtttgtatt tcaaattagc cgcagaaact 60  
 20 acaatgggcg ggcttatc 78  
  
 <210> 6  
 <211> 78  
 <212> DNA  
 25 <213> Artificial Sequence  
  
 <220>  
 <223> Synthesized polynucleotide  
  
 <400> 6  
 30 ggtttggacg caatctccct aatctaaata gatttcacag tggatccttc agaggaaact 60  
 acaatgggcg ggcttatc 78  
  
 <210> 7  
 <211> 78  
 <212> DNA  
 35 <213> Artificial Sequence  
  
 <220>  
 40 <223> Synthesized polynucleotide  
  
 <400> 7  
 ggtttggacg caatctccct aatcagacaa tattagagtg ttaccacctg tgatgaaact 60  
 45 acaatgggcg ggcttatc 78  
  
 <210> 8  
 <211> 78  
 <212> DNA  
 50 <213> Artificial Sequence  
  
 <220>  
 <223> Synthesized polynucleotide  
  
 <400> 8  
 55 ggtttggacg caatctccct aatcgtatat caagcagatg tgttcacttg gggagaaact 60

acaatgggcg ggcttatc 78

5  
 <210> 9  
 <211> 78  
 <212> DNA  
 <213> Artificial Sequence

10  
 <220>  
 <223> Synthesized polynucleotide

<400> 9  
 ggtttgacg caatctcct aatcaaagat atgctaagat agatagtttg gcttgaaact 60

15  
 acaatgggcg ggcttatc 78

20  
 <210> 10  
 <211> 78  
 <212> DNA  
 <213> Artificial Sequence

25  
 <220>  
 <223> Synthesized polynucleotide

<400> 10  
 ggtttgacg caatctcct aatcacctgt actggttatt atgcctgccca acatgaaact 60

30  
 acaatgggcg ggcttatc 78

35  
 <210> 11  
 <211> 78  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Synthesized polynucleotide

40  
 <400> 11  
 ggtttgacg caatctcct aatccttata cgtatggact taggctttgt tatagaaact 60

45  
 acaatgggcg ggcttatc 78

50  
 <210> 12  
 <211> 78  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Synthesized polynucleotide

55  
 <400> 12  
 ggtttgacg caatctcct aatcctatct gttttatcaa ttgtagcaag ttatgaaact 60

acaatgggcg ggcttatc 78

<210> 13  
 <211> 55  
 <212> DNA  
 <213> Artificial Sequence

EP 3 514 237 A1

<220>  
 <223> Synthesized polynucleotide  
  
 <400> 13  
 5 ggtttgagc caatctcct aatctgctga tgtttgatt tcaaattagc cgag 55  
  
 <210> 14  
 <211> 46  
 10 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Synthesized polynucleotide  
  
 <400> 14  
 15 gcaatctccc taatctgctg atgtttgtat ttcaaattag ccgcag 46  
  
 <210> 15  
 <211> 41  
 20 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Synthesized polynucleotide  
  
 <400> 15  
 25 gcaatctccc taatctgctg atgtttgtat ttcaaattag c 41  
  
 <210> 16  
 <211> 55  
 30 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Synthesized polynucleotide  
  
 <400> 16  
 35 ggtttgagc caatctcct aatcgatat caagcagatg tgttcacttg gggag 55  
  
 <210> 17  
 <211> 46  
 40 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Synthesized polynucleotide  
  
 <400> 17  
 45 gcaatctccc taatcgata tcaagcagat gtgttcactt ggggag 46  
  
 <210> 18  
 <211> 55  
 50 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Synthesized polynucleotide  
  
 55

EP 3 514 237 A1

<400> 18  
 ggtttggacg caatctccct aatcaaagat atgctaagat agatagtttg gcttg 55

5 <210> 19  
 <211> 46  
 <212> DNA  
 <213> Artificial Sequence

10 <220>  
 <223> Synthesized polynucleotide

<400> 19  
 gcaatctccc taatcaaaga tatgctaaga tagatagttt ggcttg 46

15 <210> 20  
 <211> 59  
 <212> DNA  
 <213> Artificial Sequence

20 <220>  
 <223> Synthesized polynucleotide

<400> 20  
 ggtttggacg caatctccct aatctttata cgtatggact taggctttgt tatagaaac 59

25 <210> 21  
 <211> 50  
 <212> DNA  
 <213> Artificial Sequence

30 <220>  
 <223> Synthesized polynucleotide

<400> 21  
 gcaatctccc taatctttat acgtatggac ttaggctttg ttatagaaac 50

35 <210> 22  
 <211> 78  
 <212> DNA  
 <213> Artificial Sequence

40 <220>  
 <223> Synthesized polynucleotide

45 <220>  
 <221> misc\_feature  
 <222> (26)..(55)  
 <223> n is a, c, g, or t

50 <400> 22  
 ggtaacgccc agtctaggtc atttgnnnnn nnnnnnnnnn nnnnnnnnnn nnnngttac 60

gggagcctgc acttaatg 78

55 <210> 23  
 <211> 23

<212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Synthesized polynucleotide

<400> 23  
 ggatacctta acgccgccta ttg

23

## Claims

1. A secretory immunoglobulin A (slgA)-binding nucleic acid molecule that binds to slgA with a dissociation constant of 37.7 nM or less.
2. The slgA-binding nucleic acid molecule according to claim 1, wherein the slgA-binding nucleic acid molecule comprises the following polynucleotide (a) or a polynucleotide consisting of a partial sequence thereof:
  - (a) a polynucleotide consisting of any of base sequences of SEQ ID NOs: 1 to 12.
3. The slgA-binding nucleic acid molecule according to claim 2, wherein the polynucleotide consisting of the partial sequence is at least one polynucleotide selected from the group consisting of the following polynucleotides (a1), (a2), (a3), and (a4):
  - (a1) a polynucleotide consisting of any of base sequences of SEQ ID NOs: 13, 14, and 15;
  - (a2) a polynucleotide consisting of either of base sequences of SEQ ID NOs: 16 and 17;
  - (a3) a polynucleotide consisting of either of base sequences of SEQ ID NOs: 18 and 19; and
  - (a4) a polynucleotide consisting of either of base sequences of SEQ ID NOs: 20 and 21.
4. The slgA-binding nucleic acid molecule according to claim 2 or 3, wherein the slgA-binding nucleic acid molecule comprises a modified base, which is a base modified with a modifying group.
5. The slgA-binding nucleic acid molecule according to claim 4, wherein the modified base is a modified purine base, which is a purine base modified with a modifying group.
6. The slgA-binding nucleic acid molecule according to claim 5, wherein the modifying group is an adenine residue.
7. The slgA-binding nucleic acid molecule according to claim 4, wherein the modified base is a modified thymine, which is a thymine base modified with a modifying group.
8. The slgA-binding nucleic acid molecule according to claim 7, wherein the modifying group is an adenine residue or a guanine residue.
9. The slgA-binding nucleic acid molecule according to any one of claims 2 to 8, wherein the polynucleotide is a DNA.
10. A secretory immunoglobulin A (slgA) analysis sensor comprising: the slgA-binding nucleic acid molecule according to any one of claims 1 to 9.
11. A slgA analysis method for analyzing slgA, comprising the step of causing a specimen and a nucleic acid molecule to come into contact with each other to detect a secretory immunoglobulin A (slgA) in the specimen, wherein the nucleic acid molecule is the slgA-binding nucleic acid molecule according to any one of claims 1 to 9, and in the detection step, the nucleic acid molecule is caused to bind to the slgA in the specimen, and the slgA in the specimen is detected by detecting the binding.
12. The slgA analysis method according to claim 11, wherein the specimen is at least one selected from the group consisting of saliva, urine, plasma, and serum.




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 1E




FIG. 1F




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 3




FIG. 4A




FIG. 4B

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2017/015934

5	A. CLASSIFICATION OF SUBJECT MATTER <i>C12N15/115</i> (2010.01) <i>i</i> , <i>C12N15/09</i> (2006.01) <i>i</i> , <i>C12Q1/68</i> (2006.01) <i>i</i> , <i>G01N33/53</i> (2006.01) <i>i</i>	
	According to International Patent Classification (IPC) or to both national classification and IPC	
10	B. FIELDS SEARCHED	
	Minimum documentation searched (classification system followed by classification symbols) <i>C12N15/115</i> , <i>C12N15/09</i> , <i>C12Q1/68</i> , <i>G01N33/53</i>	
15	Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Jitsuyo Shinan Koho 1922-1996 Jitsuyo Shinan Toroku Koho 1996-2017 Kokai Jitsuyo Shinan Koho 1971-2017 Toroku Jitsuyo Shinan Koho 1994-2017	
20	Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) JSTPlus/JMEDPlus/JST7580 (JDreamIII), CAplus/MEDLINE/WPIDS/BIOSIS (STN), GenBank/EMBL/DDBJ/GeneSeq	
	C. DOCUMENTS CONSIDERED TO BE RELEVANT	
	Category*	Citation of document, with indication, where appropriate, of the relevant passages
25	X Y	CN 105738633 A (YANG, L.), 06 July 2016 (06.07.2016), claims; example 5; paragraphs [0012], [0038]; SIGA ap-1 to SIGA ap-15 & CN 106636109 A & CN 106636110 A & CN 106636111 A & CN 106636112 A & CN 106636113 A & CN 106636114 A & CN 106701769 A & CN 106701770 A & CN 106701771 A & CN 106701772 A & CN 106701773 A & CN 106754939 A
30	Y A	IMAIZUMI, Y. et al., Efficacy of Base- Modification on Target Binding of Small Molecule DNA Aptamers, Journal of the American Chemical Society, 2013, Vol.135, No.25, pp. 9412-9419, Summary, fig. 1, page 9413, left column, lines 2 to 14
35		Relevant to claim No. 1-3, 9-11 1-12 4-12 1-3
40	<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.	
45	* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
50	Date of the actual completion of the international search 10 July 2017 (10.07.17)	Date of mailing of the international search report 18 July 2017 (18.07.17)
55	Name and mailing address of the ISA/ Japan Patent Office 3-4-3, Kasumigaseki, Chiyoda-ku, Tokyo 100-8915, Japan	Authorized officer  Telephone No.

Form PCT/ISA/210 (second sheet) (January 2015)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2017/015934

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y A	JP 2016-056136 A (National University Corporation Gunma University), 21 April 2016 (21.04.2016), claims; fig. 2 to 5; paragraph [0021] (Family: none)	4-12 1-3
Y A	Masayasu KUWAHARA, "Kobunshi no Reprogramming Hi Tennen Bunshi o Donyu shita Kakusan Aptamer no Seisei", Kobunshi, 2014, vol.63, no.10, pages 730 to 731, page 731, left column, 2nd paragraph	4-12 1-3
Y A	WO 2015/064223 A1 (National University Corporation Gunma University), 07 May 2015 (07.05.2015), claims 1, 10, 11; paragraphs [0001], [0006] & US 2016/0311845 A1 claims 1, 10, 11; paragraphs [0001], [0009]	4-12 1-3
Y A	Tokiko ISOWA, "Relationship between Job Stressor, Burnout and Physical Health Problem in Nurses: A Study Using Questionnaire and Immunological Parameter", The Japanese Society of Behavioral Medicine, 2003, 10 (1), pages 25 to 33, abstract, page 26, paragraph extending from left column to right column, page 27, right column, '3. S-IgA no Sokutei'	12 1-11
A	JP 2013-040118 A (National University Corporation Gunma University), 28 February 2013 (28.02.2013), claims (Family: none)	1-12
A	Masayasu KUWAHARA et al., "Modified nucleic acid aptamer selections using capillary electrophoresis", Electrophoresis Letters, 2015, 59 (2), pages 88 to 90, fig. 2, 3	1-12
A	Naoto HONDA et al., "Capillary Denki Eido Selection-ho ni yoru Kekkan Naihi Saibo Zoshoku Inshi Ketsugosei Enki Shushoku DNA Aptamer no Selection", 95th Annual Meeting of the Chemical Society of Japan in Spring (2015) Koen Yokoshu III, 11 March 2015 (11.03.2015), page 877, 2 J5-02	1-12

Form PCT/ISA/210 (continuation of second sheet) (January 2015)

**REFERENCES CITED IN THE DESCRIPTION**

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

**Patent documents cited in the description**

- JP 2016180892 A [0132]

**Non-patent literature cited in the description**

- **ISOWA KEIKO.** Relationship between Stressor in Duties of Nurses, Burnouts, and Physical Health Issues: Examination from Questionnaires and Immune Indicators. *Behavioral Medicine Research*, vol. 10 (1), 25-33 [0005]
- **Molecular Cloning: A Laboratory Manual.** Cold Spring Harbor Laboratory Press, 1989 [0031] [0032]

专利名称(译)	分泌型免疫球蛋白a ( SIGA ) 结合核酸分子 , 用于siga分析的传感器和用于siga的分析方法		
公开(公告)号	<a href="#">EP3514237A1</a>	公开(公告)日	2019-07-24
申请号	EP2017850476	申请日	2017-04-20
[标]申请(专利权)人(译)	日本电气方案创新株式会社 国立大学法人群馬大学		
申请(专利权)人(译)	NEC解决方案创新者, LTD. 国立大学法人群馬大学		
当前申请(专利权)人(译)	NEC解决方案创新者, LTD. 国立大学法人群馬大学		
[标]发明人	MINAGAWA HIROTAKA HORII KATSUNORI AKITOMI JOU KANEKO NAOTO WAGA IWAO KUWAHARA MASAYASU		
发明人	MINAGAWA, HIROTAKA HORII, KATSUNORI AKITOMI, JOU KANEKO, NAOTO WAGA, IWAO KUWAHARA, MASAYASU		
IPC分类号	C12N15/115 C12N15/09 C12Q1/68 G01N33/53		
CPC分类号	C12N2310/16 C12N2310/333 C12N2310/335 C12N15/09 C12N15/115 C12Q1/68 G01N33/53 C12N2310/336		
优先权	2016180892 2016-09-15 JP		
外部链接	<a href="#">Espacenet</a>		

摘要(译)

本发明提供了一种可用于检测sIgA的新型分子。本发明的结合sIgA的核酸分子的特征在于其与分泌型免疫球蛋白A ( sIgA ) 结合，解离常数为37.7nM或更低，优选包括由SEQ ID NOs的任何碱基序列组成的多核苷酸：例如，1至12或其部分序列。根据本发明的sIgA结合核酸分子，可以检测唾液中的sIgA。




FIG. 1A